Abstract YO39
Case summary
Background: Follicular thyroid carcinoma commonly presents with hematogenous metastasis to the lung and bone and rarely to the kidney. We report a case of a 61-year old woman with a metastatic follicular thyroid carcinoma to the kidney. This case report shows how a systematic approach on a patient with a renal mass can lead to a diagnosis of an unexpected primary cancer.
Case Report: A 61-year old female presented with progressively enlarging back mass. Whole abdominal ultrasound revealed right renal mass; chest CT scan showed multiple heterogeneously varisized pulmonary nodules. Ct-guided fine needle aspiration biopsy of the lung nodule was compatible with a non-small cell carcinoma. Immuno-histochemistry was positive for CK7, TTF1 and thyroglobulin and CK 20 negative favoring metastatic thyroid carcinoma. Ultrasound-guided core needle biopsy of the renal mass was compatible with thyroid carcinoma, metastatic (thyroglobulin positive). The final histopathology report after thyroidectomy was non-invasive follicular thyroid neoplasm with papillary-like nuclear features. The patient received radioactive iodine and is now with better quality of life.
Discussion: Metastatic follicular thyroid carcinoma is a rare phenomenon with only 25 cases reported in the English literature to date. Johnson et al in 1982 reported a case of follicular thyroid carcinoma with metastasis to the kidney 37 years after resection of the primary tumor. In a study by Parameswaran in 2016 on patterns of metastasis in follicular thyroid carcinoma, they found out that 40% of cases metastasized at a median of 4.5 years after initial thyroidectomy, lungs being the most common site followed by bone (25%), regional lymph nodes (13%) and brain (12%). None of the said cohort had metastasis to the kidney. The best management of FTC presenting as metastatic disease should be managed aggressively with total thyroidectomy followed by RAI which was done in our patient.
Conclusion: Given the rarity of thyroid metastasis to the kidney, a diagnostic dilemma for this case was a challenge. This case provides new data to clinicians that thyroid carcinoma can metastasize to the kidney and may mimic renal cell carcinoma although rarely reported.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract